Largely on the strength of its HIV franchise, Gilead Sciences Inc. reported a 55 percent income hike for the third quarter, but the company said beginning work on two more potential drugs for the virus will be stopped because of experimental results that have been less than encouraging. (BioWorld Today) Read More
